Amgen Current Ratio 2006-2021 | AMGN

Current and historical current ratio for Amgen (AMGN) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Amgen current ratio for the three months ending June 30, 2021 was 1.31.
Amgen Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $19.10B $14.59B 1.31
2021-03-31 $21.30B $12.87B 1.66
2020-12-31 $21.14B $11.65B 1.81
2020-09-30 $22.66B $9.95B 2.28
2020-06-30 $22.90B $10.52B 2.18
2020-03-31 $18.81B $11.83B 1.59
2019-12-31 $18.44B $12.84B 1.44
2019-09-30 $31.05B $10.74B 2.89
2019-06-30 $30.75B $10.62B 2.90
2019-03-31 $35.15B $12.71B 2.77
2018-12-31 $37.62B $13.49B 2.79
2018-09-30 $38.32B $12.43B 3.08
2018-06-30 $37.97B $11.21B 3.39
2018-03-31 $40.69B $10.48B 3.88
2017-12-31 $49.48B $9.02B 5.49
2017-09-30 $49.75B $8.19B 6.07
2017-06-30 $48.44B $7.82B 6.20
2017-03-31 $46.46B $10.52B 4.42
2016-12-31 $46.01B $11.20B 4.11
2016-09-30 $45.84B $10.54B 4.35
2016-06-30 $42.95B $10.83B 3.97
2016-03-31 $42.21B $8.52B 4.95
2015-12-31 $38.52B $8.66B 4.45
2015-09-30 $38.84B $7.17B 5.42
2015-06-30 $37.74B $6.89B 5.48
2015-03-31 $35.06B $6.34B 5.53
2014-12-31 $34.71B $7.01B 4.95
2014-09-30 $36.05B $8.55B 4.22
2014-06-30 $34.33B $7.87B 4.36
2014-03-31 $28.30B $8.20B 3.45
2013-12-31 $27.37B $7.95B 3.44
2013-09-30 $30.68B $4.84B 6.33
2013-06-30 $29.67B $4.78B 6.20
2013-03-31 $28.70B $5.14B 5.58
2012-12-31 $31.21B $8.19B 3.81
2012-09-30 $32.61B $8.37B 3.90
2012-06-30 $29.56B $8.03B 3.68
2012-03-31 $26.86B $8.30B 3.24
2011-12-31 $27.59B $5.75B 4.80
2011-09-30 $24.43B $5.32B 4.60
2011-06-30 $25.48B $4.58B 5.56
2011-03-31 $21.69B $4.25B 5.10
2010-12-31 $23.13B $6.57B 3.52
2010-09-30 $22.93B $6.26B 3.66
2010-06-30 $20.16B $5.99B 3.37
2010-03-31 $19.81B $6.56B 3.02
2009-12-31 $18.93B $3.87B 4.89
2009-09-30 $19.97B $4.90B 4.07
2009-06-30 $17.70B $4.55B 3.89
2009-03-31 $16.08B $4.67B 3.44
2008-12-31 $15.22B $4.89B 3.12
2008-09-30 $15.62B $4.95B 3.16
2008-06-30 $14.53B $5.43B 2.68
2008-03-31 $14.53B $5.95B 2.44
2007-12-31 $13.04B $6.18B 2.11
2007-09-30 $11.71B $4.23B 2.77
2007-06-30 $11.20B $4.23B 2.65
2007-03-31 $10.53B $4.61B 2.29
2006-12-31 $11.71B $6.94B 1.69
2006-09-30 $10.66B $6.29B 1.70
2006-06-30 $9.50B $5.91B 1.61
2006-03-31 $11.16B $5.38B 2.07
2005-12-31 $9.24B $3.60B 2.57
2005-09-30 $9.19B $5.11B 1.80
2005-06-30 $8.03B $4.93B 1.63
2005-03-31 $7.42B $4.78B 1.55
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $118.817B $25.424B
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76